Biomarin: Interest in new dwarfism drug for children exceeds expectations

Following European approval, interest in Biomarin's treatment for children with achondroplasia, Voxzogo, beats company expectations, it reports. US approval could be coming next month.

Photo: Rob Acket/EMA

Ascendis might gain strong competition in the shape of Biomarin's new treatment for achondroplasia, also known as dwarfism.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs